Unlocking Novel Covalent Reactivity in KRAS G12C Through Innovative Warhead Design

2:00 pm - Wednesday 21st October 2026

  • Exploring a “warhead-first” approach to covalent inhibitor design beyond traditional binder optimization strategies
  • Leveraging novel reactive chemistries and molecular trajectories to uniquely engage on-form KRAS G12C selectivity
  • Linker geometry, electrophilicity and heterocycle basicity jointly govern covalent potency against on-form KRAS G12C

Speakers:

Senior Principal Scientist
Bristol Myers Squibb